KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Other Non Operating Income: 2009-2024

Historic Other Non Operating Income for Pacira BioSciences (PCRX) over the last 16 years, with Dec 2024 value amounting to $7.5 million.

  • Pacira BioSciences' Other Non Operating Income fell 705.74% to -$983,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.4 million, marking a year-over-year decrease of 209.21%. This contributed to the annual value of $7.5 million for FY2024, which is 144.42% up from last year.
  • Pacira BioSciences' Other Non Operating Income amounted to $7.5 million in FY2024, which was up 144.42% from -$16.9 million recorded in FY2023.
  • Pacira BioSciences' Other Non Operating Income's 5-year high stood at $7.5 million during FY2024, with a 5-year trough of -$16.9 million in FY2023.
  • For the 3-year period, Pacira BioSciences' Other Non Operating Income averaged around -$6.9 million, with its median value being -$11.3 million (2022).
  • Per our database at Business Quant, Pacira BioSciences' Other Non Operating Income crashed by 323.41% in 2022 and then skyrocketed by 144.42% in 2024.
  • Yearly analysis of 5 years shows Pacira BioSciences' Other Non Operating Income stood at -$8.1 million in 2020, then skyrocketed by 66.97% to -$2.7 million in 2021, then tumbled by 323.41% to -$11.3 million in 2022, then tumbled by 49.95% to -$16.9 million in 2023, then spiked by 144.42% to $7.5 million in 2024.